T-cell therapy against cancer mutations.

Abstract

The ultimate goal of cancer therapy is to eliminate all tumor cells while sparing normal tissues. Although systemic chemotherapies can prolong survival in some patients with metastatic solid cancers, these responses are often short-lived and at the expense of significant toxicities to normal tissues because the molecules targeted by chemotherapeutic agents are not unique to the tumor. The paucity of truly unique tumor molecules that are targetable remains the major barrier toward developing effective treatments for patients with metastatic solid cancers.